Search Within

Early Drug Development Service

Formats
  1. Meeting Abstract (235)
  2. Journal Article (209)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (462)
  2. Solid Tumor Oncology Division (462)
  3. GSK Faculty (244)
  4. Department of Pathology and Laboratory Medicine (200)
  5. Human Oncology and Pathogenesis Program (193)
  6. Gynecologic Medicine Service (187)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (124)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (7)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (112)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (23)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (127)
  2. American Association for Cancer Research (101)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (462)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Circulating tumor cells and genomic profiling of patients with ERBB2 mutant, HER2 non-amplified metastatic breast cancer treated with neratinib
    Meeting Abstract

    D'Souza, A.; Shishedo, S.; Spicer, D. V.; Welter, L.; Jiang, Y.; Hyman, D. M.; Solit, D. B.; Ma, C. X.; Bose, R.; Cutler, R. E.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Carlo, M. I.; Mukherjee, S.; Kemel, Y.; Zhang, L.; Mandelker, D.; Vijai, J.; Coskey, D. T.; Pradhan, N.; Hyman, D. M.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Somatic mutations in homologous recombination pathway genes in ovarian cancer
    Meeting Abstract

    Aghajanian, C.; DeLair, D.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Makker, V.; O'Cearbhaill, R. E.; Sabbatini, P.; Soumerai, T.; Charen, A. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Characterization of NTRK fusions and therapeutic response to NTRK inhibition in hematologic malignancies
    Meeting Abstract

    Taylor, J.; Marcelus, C.; Pavlick, D.; Benayed, R.; Yoshimi, A.; Cocco, E.; Durham, B. H.; Hechtman, J. F.; Chung, Y. R.; Mullaney, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Population-scale identification of clonal hematopoiesis derived mutations in solid tumor mutation profiling
    Meeting Abstract

    Ptashkin, R.; Coombs, C. C.; Hyman, D. M.; Solit, D.; Baselga, J.; Arcila, M. E.; Ladanyi, M.; Levine, R. L.; Berger, M. F.; Zehir, A.
    Blood (2017)

    Fulltext@MSK | Save
  • Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders
    Meeting Abstract

    Diamond, E. L.; Durham, B. H.; Dogan, A.; Hyman, D. M.; Rampal, R. K.; Ulaner, G.; Brody, L.; Abdel-Wahab, O.
    Blood (2017)

    Fulltext@MSK | Save
  • Clinical and molecular characterization of patients with cancer of unknown primary in the modern era
    Journal Article

    Varghese, A. M.; Arora, A.; Capanu, M.; Camacho, N.; Won, H. H.; Zehir, A.; Gao, J.; Chakravarty, D.; Schultz, N.; Klimstra, D. S.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Single-agent dabrafenib for intracranial BRAF(V600E)-mutated histiocytosis
    Meeting Abstract

    Bhatia, A.; Ulaner, G.; Rampal, R.; Hyman, D.; Abdel-Wahab, O.; Durham, B.; Hajdenberg, J.; Ganzel, C.; Diamond, E.
    Neuro-Oncology (2017)

    Fulltext@MSK | Save
  • A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
    Journal Article

    Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
    Investigational New Drugs (2017)

    Fulltext@MSK | Save